Hemoglobinopathies: Clinical Trials

194 trials for Hemoglobinopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

194 completed. 194 Phase 2, 34 Phase 1, 19 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2194Completed 194
Phase 134Completed 34
Phase 319Completed 19

Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies

Trials (filtered) newest first · largest first

All 194 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Omega 3 Fatty Acids on Heart and Liver in Beta Thalassemia Patients
Omega 3 Fish Oil supplements, Deferasirox - Thalassemia Majors (Beta-Thalassemia Major)
Phase 2CompletedAin Shams University1002026-01-012026-10-07
A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
HBI-002 - Anemia, Sickle Cell
Phase 2CompletedHillhurst Biopharmaceuticals, Inc.132025-02-152026-08-06
Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)
zinc sulfate, Placebo - Sickle Cell Disease
Phase 2 / Phase 3CompletedIndiana University1002025-02-102026-01-30
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
Etavopivat - Sickle Cell Disease
Phase 2CompletedNovo Nordisk A/S122024-03-092026-04-08
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
Epeleuton - Sickle Cell Disease
Phase 2CompletedAfimmune352024-01-102026-05-04
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
Voxelotor - Sickle Cell Disease
Phase 2CompletedInova Health Care Services62023-10-232026-08-31
Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia
L-glutamine - Pulmonary Artery Pressure, Thalassemia
Phase 2 / Phase 3CompletedMazandaran University of Medical Sciences82023-08-152025-10-07
Hydroxyurea and EPO in Sickle Cell Disease
Hydroxyurea, Epoetin Alfa-BioSimilar - Anemia, Sickle Cell, Sickle Cell Disease
Phase 1 / Phase 2CompletedJulia Xu172023-05-252026-01-07
Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
Hydroxycarbamide - Sickle Cell Disease
Phase 2CompletedTheravia332022-07-082022-11-23
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo - Sickle Cell Disease
Phase 2CompletedNovo Nordisk A/S962022-07-072026-07-22
Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients
CN128 Tablets - Thalassemia, Iron Overload
Phase 2CompletedHangzhou Zede Pharma-Tech Co., Ltd.162022-06-132025-03-14
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
Etavopivat tablets - Sickle Cell Disease, Thalassemia
Phase 2CompletedForma Therapeutics, Inc.532022-03-282025-12-16
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER - Sickle Cell Disease
Phase 2CompletedBausch Health Americas, Inc.442022-03-222024-09-19
A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
Crovalimab, Placebo - Sickle Cell Disease
Phase 2CompletedHoffmann-La Roche952022-03-092026-04-30
Interest of Famotidine in Children With Sickle Cell Disease
Famotidine 400 mg/50 mL - Sickle Cell Disease
Phase 2 / Phase 3CompletedAssistance Publique - Hôpitaux de Paris302022-01-122025-10-08
Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain
Guided Relaxation, Acupuncture - Sickle Cell Disease
Phase 2CompletedUniversity of Illinois at Chicago3792021-11-242026-03-03
Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease
VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg - Sickle Cell Disease
Phase 2CompletedVifor (International) Inc.252021-11-182025-02-18
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
Losartan - Sickle Cell Disease, Diffuse Myocardial Fibrosis
Phase 2CompletedChildren's Hospital Medical Center, Cincinnati142021-09-012026-06-12
Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.
Thalidomide 100mg, Hydroxyurea - Beta-Thalassemia
Phase 2CompletedNational Institute of Blood and Marrow Transplant (NIBMT), Pakistan242021-09-012024-03-12
Management of Severe Acute Malnutrition in SCD, in Northern Nigeria
hydroxyurea (20mg/kg/day), Ready-to-use therapeutic food - Sickle Cell Anemia, Severe Acute Malnutrition
Phase 2CompletedVanderbilt University Medical Center1322021-08-182024-03-27

Showing 20 of 194. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (140)  ·  beta-Thalassemia (42)  ·  Thalassemia (39)  ·  Iron Overload (16)  ·  Anemia (15)  ·  Hematologic Diseases (14)  ·  Vaso-Occlusive Crises (13)  ·  Genetic Diseases, Inborn (11)  ·  Anemia, Diamond-Blackfan (8)  ·  Acute Chest Syndrome (6)  ·  Anemia, Aplastic (4)  ·  Anemia, Hemolytic (4)  ·  Bone Marrow Failure Disorders (4)  ·  Myelodysplastic Syndromes (4)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (194)  ·  Hemic and Lymphatic Diseases (194)  ·  Anemia, Hemolytic, Congenital (190)  ·  Anemia, Hemolytic (187)  ·  Genetic Diseases, Inborn (183)  ·  Hematologic Diseases (180)  ·  Anemia (176)  ·  Thalassemia (30)  ·  Nutritional and Metabolic Diseases (28)  ·  Pathological Conditions, Signs and Symptoms (26)  ·  Metabolic Diseases (24)  ·  Iron Metabolism Disorders (16)  ·  Bone Marrow Diseases (15)  ·  Pathologic Processes (15)

Interventions

Hydroxyurea (23)  ·  Deferasirox (17)  ·  Busulfan (10)  ·  Bone Marrow Transplantation (8)  ·  Deferoxamine (8)  ·  fludarabine (8)  ·  Antilymphocyte Serum (7)  ·  Cyclophosphamide (7)  ·  fludarabine phosphate (7)  ·  Alemtuzumab (6)  ·  Whole-Body Irradiation (6)  ·  2,2-dimethylbutyric acid (5)  ·  Saline Solution (5)  ·  Arginine (4)  ·  Cholecalciferol (4)

Sponsors

Novartis Pharmaceuticals (17)  ·  National Heart, Lung, and Blood Institute (NHLBI) (9)  ·  UCSF Benioff Children's Hospital Oakland (8)  ·  Assistance Publique - Hôpitaux de Paris (6)  ·  Medical College of Wisconsin (4)  ·  Boston University (3)  ·  Carelon Research (3)  ·  Children's Hospital Medical Center, Cincinnati (3)  ·  Emory University (3)  ·  HemaQuest Pharmaceuticals Inc. (3)  ·  Johns Hopkins University (3)  ·  Prolong Pharmaceuticals (3)  ·  St. Jude Children's Research Hospital (3)  ·  University of North Carolina, Chapel Hill (3)  ·  AstraZeneca (2)

Countries

United States (133)  ·  Italy (24)  ·  United Kingdom (23)  ·  Lebanon (21)  ·  France (19)  ·  Canada (18)  ·  Thailand (12)  ·  Turkey (Türkiye) (12)  ·  Greece (11)  ·  Egypt (9)  ·  Germany (6)  ·  Jamaica (6)  ·  Brazil (5)  ·  Pakistan (5)  ·  Saudi Arabia (5)

Top investigators

Claudia Morris, MD (3)  ·  Mark Walters (3)  ·  Ahmed F Mahmoud Hussein, MS.c (2)  ·  Helen Thackray, MD (2)  ·  Hemant Misra, PhD (2)  ·  Kenneth I Ataga, MBBS (2)  ·  Lakshmanan Krishnamurti, MD (2)  ·  Margaret T Lee, MD (2)  ·  Mary Horowitz, MD (2)  ·  Mitchell S Cairo, MD (2)  ·  Nancy Olivieri, MD (2)

Results publications

PMID 34175041, PMID 36240296, PMID 37975597, PMID 26348869, PMID 33283989, PMID 34922648, PMID 36355805, PMID 36529836, PMID 38775255, PMID 40569673, PMID 17233848, PMID 18192510, PMID 18550258, PMID 20421452, PMID 20955402, PMID 21173101, PMID 21364138, PMID 21393329, PMID 21477202, PMID 21700776, PMID 21742281, PMID 22129980, PMID 22251482, PMID 22571408, PMID 2265118, PMID 22887019, PMID 22924607, PMID 23151373, PMID 23416852, PMID 23553596, PMID 23585527, PMID 23645695, PMID 23828223, PMID 24370862, PMID 24385534, PMID 24443249, PMID 24445353, PMID 24452753, PMID 24939325, PMID 24976388, PMID 24988449, PMID 25212456, PMID 25345697, PMID 25492271, PMID 25701866, PMID 25733584, PMID 26232172, PMID 26431718, PMID 26719803, PMID 27326168

NIH funding

2014 (3), 2017 (3), U01HL065238 (3), 2016 (2), 2018 (2), U24CA076518 (2), 1UG3AT011265-01 (1), 2004 (1), 2015 (1), 2019 (1), 3UL1RR025005 (1), K01HL096434 (1), K23HL119351 (1), K23HL136787 (1), K24AT009893 (1)